Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

2018 NIAID Omnibus Broad Agency Announcement

Active
HHS-NIH-NIAID-BAA2018Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The 2018 NIAID Omnibus Broad Agency Announcement (BAA) solicits research proposals in multiple areas related to infectious diseases, with a particular focus on influenza vaccine innovation. Initially issued on June 1, 2018, the solicitation underwent several amendments, the most significant of which introduced Research Area 003, entitled "Collaborative Influenza Vaccine Innovation Centers (CIVICs)." This addition aimed to foster collaboration among organizations interested in advancing influenza vaccine development. Subsequent amendments clarified submission requirements, addressed questions related to various research areas, provided contact information for collaboration opportunities, and revised sections concerning cost assumptions and proposal content. Notably, the PHS Human Subjects and Clinical Trials Information Form was excluded from the technical proposal page limit, streamlining application procedures. The solicitation and its amendments emphasize transparency and collaboration by facilitating communication among potential research partners and clarifying submission guidelines. Key government contacts are provided, including contracting officers and specialists, to support applicants throughout the solicitation process. The contracting team includes Julie Catherine Rodriguez and George Kennedy, who serve as contract specialist and contracting officer respectively, while Michael C. Finn is the point of contact for collaboration inquiries related to CIVICs. The solicitation targets organizations performing research under the NAICS code 541715 and remains a vital opportunity for entities contributing to infectious disease research and vaccine innovation under the National Institute of Allergy & Infectious Diseases.

General Info

NIAID BAA 2018 solicits infectious disease research, focusing on influenza vaccine innovation and collaboration.

Agency

N/A

Contract Value

$76,786,980.25

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

9 updates
PhaseSolicitation
Posted

Presolicitation

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Type Changed

Presolicitation → Solicitation

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyN/A
Contacts2 people available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Julie Catherine RodriguezContract Specialist
George KennedyContracting Officer

Full Description

Show more
National Institute of Allergy & Infectious Diseases (NIAID) 2018 Omnibus Broad Agency Announcement - HHS-NIH-NIAID-BAA2018 Activity Log: 1. Solicitation Issuance: 06/01/2018 2. Amendment No.1 Issuance: 07/03/2018 - Purpose of Amendment 1: To add RESEARCH AREA 003, "Collaborative Influenza Vaccine Innovation Centers (CIVICs)" to the 2018 Omnibus Broad Agency Announcement - Included Attachments: Revised solicitation: "HHS-NIH-NIAID-BAA2018 - Amendment One" 3. Amendment No.2 Issuance: 07/03/2018 - Purpose of Amendment 2: To provide responses to questions received regarding Research Areas 001 and 002 of this solicitation. 4. Amendment No.3 Issuance: 07/20/2018 - Purpose of Amendment 3: This amendment is applicable to RESEARCH AREA 003, "Collaborative Influenza Vaccine Innovation Centers (CIVICs)". This amendment provides a Government point of contact for organizations wishing to advertise their interest in collaborating with other interested organizations. Michael C. Finn, M.B.A., Chief Contracting Officer Phone: (240) 669-5125 Email: finnm@niaid.nih.gov 5. Amendment No.4 Issuance: 07/24/2018 - Purpose of Amendment 4: To provide responses to questions received regarding Research Areas 001 and 002 of this solicitation. 6. Amendment No.5 Issuance: 08/02/2018 - Purpose of Amendment 5: To revise solicitation HHS-NIH-NIAID-BAA2018; clarifying that the PHS Human Subjects and Clinical Trials Information Form is NOT included in the Technical Proposal page limit, and providing updated hyperlinks within the solicitation. - Included Attachments: Revised solicitation: "HHS-NIH-NIAID-BAA2018, Amendment 1 (Revised 08-02-2018)" 7. Amendment No.6 Issuance: 08/31/2018 - Purpose of Amendment 6: This amendment is applicable to RESEARCH AREA 003, "Collaborative Influenza Vaccine Innovation Centers (CIVICs)". The purpose of this amendment is to revise Section 3.2 of solicitation HHS-NIH-NIAID-BAA2018, and provide responses to questions received in response to Research Area 003. - Included Attachments: Revised solicitation: "HHS-NIH-NIAID-BAA2018, Amendment 1 (Revised 08-31-2018)" 8. Amendment No.7 Issuance: 08/31/2018 - Purpose of Amendment 7: This informational amendment is applicable to RESEARCH AREA 003, "Collaborative Influenza Vaccine Innovation Centers (CIVICs)". This purpose of this informational amendment is to make available contact information provided by organizations wishing to advertise their interest in collaborating with other interested organizations. - Included Attachments: "Organizations Advertising Their Interest in Collaborating" 9. Amendment No.8 Issuance: 10/24/2018 - Purpose of Amendment 8: This amendment is applicable to RESEARCH AREA 003, "Collaborative Influenza Vaccine Innovation Centers (CIVICs)". This purpose of this amendment is to revise Section 3.2.3.4. UNIFORM COST ASSUMPTIONS, and provide responses to questions received in response to Research Area 003. 10. Amendment No.9 Issuance: 11/05/2018 - Purpose of Amendment 9: This amendment is applicable to RESEARCH AREA 003, "Collaborative Influenza Vaccine Innovation Centers (CIVICs)". This purpose of this amendment is to revise Section 3.2.3.4. UNIFORM COST ASSUMPTIONS, and provide responses to questions received in response to Research Area 003.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.
W6QK Acc Wva

POSTED

about 18 hours ago

DEADLINE

in 11 months
View Details
NAICS: 541715
New
Grant
Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-002
Solicitation RFA-DC-28-002 is a Notice of Funding Opportunity from the National Institutes of Health, specifically the National Institute on Deafness and Other Communication Disorders, to establish a Coordinating Center for the NIDCD National Human Ear Resource Network. This collaborative network provides human inner and middle ear tissues to researchers for basic and clinical studies aimed at advancing the treatment of auditory and vestibular disorders. The Coordinating Center is responsible for maintaining network cohesiveness through the planning of workshops, symposia, and regular meetings, providing updates to laboratories, and managing communication with the public and scientific community regarding tissue donation. The maximum project period is five years, with a budget limit of 200,000 dollars in direct costs per year. Applicants, including for-profit organizations and small businesses, must maintain active registrations in SAM, eRA Commons, and Grants.gov. Proposals are evaluated based on the significance of the proposed center and the qualifications of the investigators, with additional reviews for human subject protections, inclusion policies, and the use of vertebrate animals. Key requirements include a structured Data Management and Sharing Plan and adherence to cybersecurity guidelines, including a 48-hour incident reporting window. The application process is entirely electronic and requires several standard PHS and SF424 forms, with a response deadline of March 5, 2027.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 4 months
View Details
NAICS: 541715
New
Grant
National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
Solicitation # RFA-DC-28-001
Solicitation RFA-DC-28-001 is a Notice of Funding Opportunity issued by the National Institutes of Health under the Department of Health and Human Services to support the NIDCD National Human Ear Resource Network. The objective is to maintain a collaborative network of laboratories that serve as a national technological resource, providing human inner and middle ear tissues to researchers for basic and clinical studies to advance the treatment of auditory and vestibular disorders. The scope of work includes processing human temporal bones from the National Hearing and Balance Organ Donor Program, uploading images and medical data to EarBase, sharing gene-expression data via the gEAR repository, and providing technical instruction to increase the number of skilled researchers in the field. The NIDCD intends to commit 3.6 million dollars in FY 2028 to fund up to six awards, with a maximum project period of five years. Individual awards are limited to 450,000 dollars in direct costs per year, with an additional 150,000 dollars available for specific subawards. Applications are due on March 05, 2027, and November 01, 2027, with staggered start dates ranging from July 2027 to July 2028. Evaluation is based on the experience of the investigators, the adequacy of the institutional environment, and the protection of human subjects. Applicants must maintain active SAM registration and a Unique Entity Identifier, and they must provide a Data Management and Sharing Plan and a Material Transfer Agreement. Compliance with the Cybersecurity Act of 2015 is required, including the development of an incident response plan and notification of cybersecurity incidents within 48 hours of discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in about 1 year
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS